Cargando…

The potential therapeutic effect of platelet-rich plasma in the treatment of post-COVID-19 parosmia

BACKGROUND: COVID-19-related olfactory dysfunction is an emerging problem with a significant impact on the quality of life of affected individuals. Different lines of treatment have been used with varying results. This study aimed to assess the potential therapeutic effect of PRP in the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Abo El Naga, Heba A., El Zaiat, Reham S., Hamdan, Ahmad M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556146/
http://dx.doi.org/10.1186/s43163-022-00320-z
_version_ 1784807007925043200
author Abo El Naga, Heba A.
El Zaiat, Reham S.
Hamdan, Ahmad M.
author_facet Abo El Naga, Heba A.
El Zaiat, Reham S.
Hamdan, Ahmad M.
author_sort Abo El Naga, Heba A.
collection PubMed
description BACKGROUND: COVID-19-related olfactory dysfunction is an emerging problem with a significant impact on the quality of life of affected individuals. Different lines of treatment have been used with varying results. This study aimed to assess the potential therapeutic effect of PRP in the treatment of post-COVID olfactory dysfunction. This work aimed to assess the potential therapeutic effect of platelet-rich plasma (PRP) in treating post-COVID-19 parosmia. A pilot study was conducted on 60 patients with post-COVID parosmia without responding to a 3-month course of olfactory training, topical corticosteroids, omega-three, vitamin B12, and zinc supplementation. The patients were distributed randomly and equally among 2 groups. The case group was subjected to three PRP injections in the olfactory cleft at 3 weeks intervals. The control group continued the pre-study treatment protocol for 6 weeks. The degree of parosmia was assessed before and after treatment subjectively using a visual analog scale (VAS) from 0 to 10. Reaching 0–1 on the visual analog scale was a complete improvement. The primary outcome was assessing the post-treatment score for parosmia 1 month after the third injection in the case group. The second outcome was the comparison between both groups regarding the degree of improvement 1 month after cessation of treatment. RESULTS: There was a highly significant improvement in VAS for parosmia (p < 0.00001) in the case group and a significant improvement in VAS for parosmia in the control group (p = P = 0.00148). There was a significant difference between both groups regarding the degree of improvement favoring the case group (p = 0.002). CONCLUSION: Platelet-rich plasma injection in the olfactory cleft offers a therapeutic option for treating patients with post-COVID-19 olfactory parosmia who failed to respond to traditional conservative treatment.
format Online
Article
Text
id pubmed-9556146
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-95561462022-10-13 The potential therapeutic effect of platelet-rich plasma in the treatment of post-COVID-19 parosmia Abo El Naga, Heba A. El Zaiat, Reham S. Hamdan, Ahmad M. Egypt J Otolaryngol Original Article BACKGROUND: COVID-19-related olfactory dysfunction is an emerging problem with a significant impact on the quality of life of affected individuals. Different lines of treatment have been used with varying results. This study aimed to assess the potential therapeutic effect of PRP in the treatment of post-COVID olfactory dysfunction. This work aimed to assess the potential therapeutic effect of platelet-rich plasma (PRP) in treating post-COVID-19 parosmia. A pilot study was conducted on 60 patients with post-COVID parosmia without responding to a 3-month course of olfactory training, topical corticosteroids, omega-three, vitamin B12, and zinc supplementation. The patients were distributed randomly and equally among 2 groups. The case group was subjected to three PRP injections in the olfactory cleft at 3 weeks intervals. The control group continued the pre-study treatment protocol for 6 weeks. The degree of parosmia was assessed before and after treatment subjectively using a visual analog scale (VAS) from 0 to 10. Reaching 0–1 on the visual analog scale was a complete improvement. The primary outcome was assessing the post-treatment score for parosmia 1 month after the third injection in the case group. The second outcome was the comparison between both groups regarding the degree of improvement 1 month after cessation of treatment. RESULTS: There was a highly significant improvement in VAS for parosmia (p < 0.00001) in the case group and a significant improvement in VAS for parosmia in the control group (p = P = 0.00148). There was a significant difference between both groups regarding the degree of improvement favoring the case group (p = 0.002). CONCLUSION: Platelet-rich plasma injection in the olfactory cleft offers a therapeutic option for treating patients with post-COVID-19 olfactory parosmia who failed to respond to traditional conservative treatment. Springer Berlin Heidelberg 2022-10-12 2022 /pmc/articles/PMC9556146/ http://dx.doi.org/10.1186/s43163-022-00320-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Abo El Naga, Heba A.
El Zaiat, Reham S.
Hamdan, Ahmad M.
The potential therapeutic effect of platelet-rich plasma in the treatment of post-COVID-19 parosmia
title The potential therapeutic effect of platelet-rich plasma in the treatment of post-COVID-19 parosmia
title_full The potential therapeutic effect of platelet-rich plasma in the treatment of post-COVID-19 parosmia
title_fullStr The potential therapeutic effect of platelet-rich plasma in the treatment of post-COVID-19 parosmia
title_full_unstemmed The potential therapeutic effect of platelet-rich plasma in the treatment of post-COVID-19 parosmia
title_short The potential therapeutic effect of platelet-rich plasma in the treatment of post-COVID-19 parosmia
title_sort potential therapeutic effect of platelet-rich plasma in the treatment of post-covid-19 parosmia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556146/
http://dx.doi.org/10.1186/s43163-022-00320-z
work_keys_str_mv AT aboelnagahebaa thepotentialtherapeuticeffectofplateletrichplasmainthetreatmentofpostcovid19parosmia
AT elzaiatrehams thepotentialtherapeuticeffectofplateletrichplasmainthetreatmentofpostcovid19parosmia
AT hamdanahmadm thepotentialtherapeuticeffectofplateletrichplasmainthetreatmentofpostcovid19parosmia
AT aboelnagahebaa potentialtherapeuticeffectofplateletrichplasmainthetreatmentofpostcovid19parosmia
AT elzaiatrehams potentialtherapeuticeffectofplateletrichplasmainthetreatmentofpostcovid19parosmia
AT hamdanahmadm potentialtherapeuticeffectofplateletrichplasmainthetreatmentofpostcovid19parosmia